- News
- Melanoma
Tag:
Melanoma
-
Replimune Group Inc (NASDAQ: REPL) saw its stock jump 60% after the U.S. Food and Drug Administration (FDA) accepted the company’s resubmission of a Biologics License Application (BLA) for its experimental melanoma treatment, RP1.20 Oct 2025-17:56
-